Grey Matters by OBD
Welcome to our newsletter, Grey Matters by OBD.
Each month we share what's new at OBD, the science behind CDM made simple, and what we're hearing from our partners in pharma and clinical care.
We won the CNS Summit Innovation Showcase
OBD was one of ten companies selected to present on the main stage, and we were named the winner. We focused on a blind spot in neuroscience trials. PET and blood biomarkers show specific molecules, and structural MRI shows volume. Neither shows how cortical tissue itself is changing.
CDM, our Cortical Disarray Measurement, fills that gap by measuring cortical microstructure from diffusion MRI, region by region and over repeat scans. For drug development, that means a way to select the right patients, measure the underlying biology and track how it changes during treatment.
New FTD data with Penn
At ISFTD 2026, Dr. David Irwin and colleagues at the Penn Frontotemporal Degeneration Center presented a study of 36 autopsy-confirmed bvFTD cases (19 FTLD-tau, 17 FTLD-TDP). The study measured CDM during life and compared it with the pathology found at autopsy. CDM patterns tracked how that pathology was distributed across the cortical layers, and the link was strongest in FTLD-TDP.
It's an early result, but it connects something we can measure noninvasively in living patients to the underlying pathology, which is what an imaging biomarker needs to do.
NeuroTherapia shares our work together at CTAD
At the biotech showcase session on Tuesday at CTAD 2026 in Boston, Tony Giordano, President and CEO of NeuroTherapia, talked about our work together. OBD has worked with NeuroTherapia for several years, with CDM supporting MRI analysis in its Alzheimer's program.
It was great to hear a drug developer describe in their own words how CDM fits into their program.